ArticleJournal of virology2025
HCC-derived SNU cell lines as model systems to study HBV life cycle.
Article in Journal of virology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Natural immune escape mutations in the envelope proteins of hepatitis B virus (HBV) regulate the assembly and infectivity of human hepatitis delta virus (HDV).Journal of virology · 2026Article
- Drug resistance mutations of hepatitis B virus (HBV) influence the yield of the virions of the human hepatitis delta virus (HDV) and their infectivity.Journal of virology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Human SNU cell lines, derived from hepatocellular carcinomas associated with chronic hepatitis B virus (HBV) infection, were examined. The analysis of intracellular RNA and DNA markers of HBV replication and examination of HBV RNA readss coverage of selected regions on HBV-related RNAs and polyadenylation positions within HBV sequence using RNA-sequencing suggested the absence of HBV replication in SNU-423, SNU-368, SNU-398, SNU-182, SNU-449, SNU-475, SNU-354, SNU-739, and SNU-387 cells, while SNU-761 and SNU-886 still could maintain residual HBV replication. The undetectable intracellular HBV core antigen (HBcAg) and absence of significant levels of secreted core-associated and virion-associated HBV DNA confirmed the absence or profound suppression of HBV replication in parental SNU cell lines. Various 5'-human-HBV-3' and 5'-HBV-human-3' RNAs transcribed from integrated HBV DNA were found in most of the SNU cell lines. The 5'-HBV-human-3' junctions suggested that several SNU cell lines could generate 5'-HBV-human-3' RNAs encoding HBV envelope proteins. The known and novel spliced HBV RNAs were detected in SNU-886, SNU-739, SNU-387, SNU-761, and SNU-354 cells. At least some of them were generated independently of HBV replication. None of the SNU cell lines supported efficient HBV replication after transfection with the vector that initiates efficient HBV replication in Huh7 cells. This was reflected by three distinct accumulation patterns of HBV replication markers, undetectable intracellular HBcAg, and by the lack of considerable levels of secreted core-bound and virion-associated HBV DNA. Overall, SNU cell lines represent valuable model systems for detailed analysis of integrant-transcribed HBV RNAs, spliced HBV RNAs, and mechanisms of suppression of HBV genome replication.IMPORTANCESNU cell lines without ongoing hepatitis B virus (HBV) genome replication are invaluable experimental systems that allow detailed study of the biogenesis and properties of integrant-transcribed 5'-human-HBV-3' and 5'-HBV-human-3' RNAs and mechanisms generating spliced HBV-related RNA species independently of concomitant viral replication. Three unique patterns of intracellular accumulation of HBV replication markers were observed in SNU cell lines transfected with the vector that initiates efficient HBV genome replication in Huh7 cells: (i) very low levels of pre-genomic RNA (pgRNA), total HBV RNA, replication-derived RNAs (rd-RNAs), covalently closed circular DNA (cccDNA), and core-associated HBV DNA; (ii) moderate pgRNA, high total HBV RNA, rd-RNAs, and cccDNA, but very low core-associated HBV DNA; and (iii) very low pgRNA, total HBV RNA, rd-RNAs, and core-associated HBV DNA, but moderate/high cccDNA likely reflect three natural host-mediated mechanisms suppressing HBV replication, the analysis of which should advance our understanding of HBV-host interactions and could be informative for the search for novel anti-HBV interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.